Breast　cancer　is　one　of　the　most　common　cancers　in　women　globally,　posing　significant　challenges　to　treatment　because　of　the　diverse　and　complex　pathological　and　molecular　subtypes.　The　emergence　of　immune　checkpoint　inhibitors　(ICIs)　has　revolutionized　the　treatment　of　breast　cancer,　particularly　for　triple-negative　breast　cancer　(TNBC),　significantly　improving　patient　outcomes.　However,　the　overall　tumor　response　rate　remains　suboptimal　due　to　drug　resistance　to　ICIs.　This　resistance　is　primarily　due　to　the　immune-suppressive　tumor　microenvironment　(TME),　tumor　cells＇　ability　to　evade　immune　surveillance,　and　other　complex　immune　regulatory　mechanisms.　To　address　these　challenges,　clinical　researchers　are　actively　exploring　combinatorial　therapeutic　strategies　with　ICIs.　Tumor　local　ablation　(TLA)　technology　is　anticipated　to　overcome　resistance　to　ICIs　and　enhance　therapeutic　efficacy　by　ablating　tumor　tissue,　releasing　tumor　antigens,　remodeling　the　TME,　and　stimulating　local　and　systemic　immune　responses.　Combination　therapy　with　TLA　and　ICIs　has　demonstrated　promising　results　in　preclinical　breast　cancer　studies,　underscoring　the　feasibility　and　importance　of　addressing　drug　resistance　mechanisms　in　breast　cancer.　This　provides　novel　strategies　for　breast　cancer　treatment　and　is　expected　to　drive　further　advancements　in　the　field.